GlassScriptPhysician profile
Madeline S Wood
NPI 1518947373
$2,040.59
in general payments reported to CMS, 2019-2025
28 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $263 · 2021: $164 · 2022: $242 · 2023: $398 · 2024: $417 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.69 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $265.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $212.54 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.25 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $110.50 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $102.84 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $100.20 | 2023-2025 | Octrode, Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $98.40 | 2021-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $80.38 | 2020-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $68.05 | 2019-2024 | |
| Inspire Medical Systems, INC. | $61.84 | 2024-2025 | Inspire |
| Pfizer INC. | $59.00 | 2020-2021 | |
| Allergan, INC. | $54.27 | 2019-2020 | |
| Exact Sciences Corporation | $44.95 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $42.21 | 2024 | Camzyos, Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.92 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.80 | 2022 | |
| Bausch Health US, LLC | $32.99 | 2022-2023 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $29.72 | 2024 | |
| Aytu Biopharma, INC. | $26.39 | 2020 | |
| Dexcom, INC. | $24.48 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $20.06 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $17.65 | 2022 | |
| Corium, LLC | $17.62 | 2022 | |
| Hologic Sales and Service, LLC | $16.27 | 2025 | Thinprep 2000 Processor, Aptima |
| Ucb, INC. | $14.80 | 2023 | Nayzilam |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2020 | |
| Neurelis, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.